• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Defence Therapeutics Inc
Envirometal Technologies Inc
F & M Bank Corp
Femto Technologies Inc. - Common Stock
First Trust Energy Infrastructure Fund Common Shares of Beneficial Interest
Innovative Pymnt Solution
Lamar Advertising Company - Class A Common Stock
Matthews Korea Active ETF
Overactive Media Corp
Plurilock Sec Inc
Wishpond Technologies Ltd
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

8.220 -0.090 (-1.08%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,943,797
Open 8.210
Bid (Size) 8.220 (200)
Ask (Size) 8.230 (200)
Prev. Close 8.310
Today's Range 8.050 - 8.355
52wk Range 1.950 - 12.43
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
October 21, 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
October 16, 2026
From ImmunityBio, Inc.
Via Business Wire

Performance

52-Week Range 33.9% below 52-week high
8.220
1.9552W Low 12.4352W High
1 Week 15.2% below 1-week high
8.021W Low 9.701W High

ImmunityBio, Inc. - Common Stock (IBRX) traded between $1.95 and $12.43 over the past 52 weeks and last traded at $8.22, 33.9% below its 52-week high. Over the past week it ranged between $8.02 and $9.70.

Past 12 Months
-2.4%
-4.8%
+15.8%
+10.5%
+306.9%
+243.9%
1W -$0.20
1M -$0.41
3M +$1.12
6M +$0.78
YTD +$6.20
1Y +$5.83

IBRX was +243.9% over the past year, +10.5% over six months, +306.9% year to date, -2.4% in the last week.

12 Months vs Market
IBRX
+243.9%
DIA
+11.6%
SPY
+13.1%
QQQ
+15.4%
IWM
+11.9%

Over the past 12 months IBRX returned +243.9% versus DIA (Dow) +11.6%, SPY (S&P 500) +13.1%, QQQ (Nasdaq 100) +15.4% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 0.52× 3-mo avg
Today 5,943,797 3-mo avg 11.5M
1W
12.8M
1M
15.3M
3M
11.5M
6M
12.1M
YTD
20.4M
1Y
18.7M

IBRX most recently traded 5,943,797 shares against a 3-month average daily volume of 11.5M.

More News

Read More
News headline image
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
October 14, 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
October 08, 2026
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio (NASDAQ:IBRX) Screens as a High-Growth Momentum Stock Passing Minervini’s Trend Template ↗
July 03, 2026
Via Chartmill
News headline image
2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus
October 01, 2026
Via AB Newswire
News headline image
Archer Aviation (NYSE: ACHR) Among IBRX, JOBY, SCKT Leading Technology Stocks – Plus More in Focus
August 10, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
August 10, 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
Bull Finder: IBRX, ANY, GTE, JLHL Plus More Surging Stocks Inside
August 05, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
August 04, 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
July 29, 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
June 08, 2026
From Biotech Insider
Via GlobeNewswire
News headline image
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
June 01, 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
May 26, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
May 26, 2026
From Rosen Law Firm
Via Business Wire
News headline image
IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
May 26, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 25, 2026
From Schall Law
Via GlobeNewswire
News headline image
ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
May 22, 2026
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th
May 22, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
May 22, 2026
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
May 22, 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
May 22, 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
May 21, 2026
From SkyMedia, LLC
Via GlobeNewswire
News headline image
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 21, 2026
From Schall Law
Via GlobeNewswire
News headline image
Why ImmunityBio Stock is Soaring Higher Today ↗
May 20, 2026
Via The Motley Fool

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?
Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
What exchange does ImmunityBio, Inc. - Common Stock trade on?
ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 8.220
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 10/23/26 04:00 PM ET
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 3.22B
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap